Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2007

View Archived Issues

N-Acetylcysteine to be evaluated in clinical study for the treatment of rhabdomyolysis

Carraguard vaginal gel acceptable to healthy Thai couples

AMG-531 increases platelet counts in immune thrombocytopenic purpura patients

CoGenesys files to conduct clinical studies of Neugranin in Europe

Viprovex studied for adjuvant utility in pandemic influenza

Phase II trial to examine A-002 in coronary atherosclerosis patients

Oscient grants Factive European commercialization rights to Menarini

Alkermes and Indevus collaborate to develop inhaled trospium chloride for COPD

BSI-201 studied with cytotoxic regimens for solid tumors

Elusys and Pfizer to develop new therapeutics based on HP Antibody technology

Inspire updates progress in dry eye program

Pluristem submits pre-IND document for PLX-I

Victory Pharma's IND cleared for MGX-006

Raven and Wyeth enter monoclonal antibody agreement

SPI-1005 completes phase I testing for noise-induced hearing loss

Sunesis outlicenses LFA-1 inhibitor program to SARcode

Aveo acquires license to VEGF receptor inhibitor KRN-951

Immune Response receives milestone payment from NovaRx

Boston Life Sciences acquires rights to develop and commercialize Cethrin

New analgesic agents described in recent patents

Horizon raises funds to support phase III program for HZT-501

Novel agents for cardiovascular disorders claimed

Recent patents reveal discovery of novel antidiabetic agents

Cerepro phase III trial progresses

Pharmacopeia and Wyeth to develop JAK3 inhibitor products

Positive findings for pertuzumab plus gemcitabine in phase II trial